

**Manuscript no. HAEMATOL/2010/029660 entitled "Evaluation of gene expression signatures predictive for cytogenetic and molecular subtypes of pediatric acute myeloid leukemia"**

**Authors: Brian V. Balgobind, Marry M. Van den Heuvel-Eibrink, Renee X. De Menezes, Dirk Reinhardt, Iris H.I.M. Hollink, Susan T.J.C.M. Arentsen-Peters, Elisabeth R. van Wering, Gertjan J.L. Kaspers, Jacqueline Cloos, Evelien S.J.M. de Bont, Jean-Michel Cayuela, Andre Baruchel, Claus Meyer, Rolf Marschalek, Jan Trka, Jan Stary, H. Berna Beverloo, Rob Pieters, C. Michel Zwaan and Monique L. den Boer**

**Information about the contributions of each person named as having participated in the study**

**1) Guarantor(s)**, i.e., person(s) who is (are) responsible for the integrity of the work as a whole:

- Monique L. den Boer, Pediatric Oncology/Hematology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands; m.l.denboer@erasmusmc.nl
- Marry M. Van den Heuvel-Eibrink, Pediatric Oncology/Hematology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands; m.vandenheuvel@erasmusmc.nl
- C. Michel Zwaan, Pediatric Oncology/Hematology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands; c.m.zwaan@erasmusmc.nl
- Rob Pieters, Pediatric Oncology/Hematology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands; rob.pieters@erasmusmc.nl
- Brian V. Balgobind, Pediatric Oncology/Hematology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands; b.balgobind@erasmusmc.nl

According to the International Committee of Medical Journal Editors (ICMJE)

([http://www.icmje.org/ethical\\_1author.html](http://www.icmje.org/ethical_1author.html)): "Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3 ..... Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship".

**The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.**

2) Authors who participated in the **conception of the study**: Monique L. den Boer, Marry M. Van den Heuvel-Eibrink, C. Michel Zwaan, Rob Pieters, and Elisabeth R. van Wering

3) **Design & Methods**. The following authors were responsible for specific investigations (please detail):

- Monique L. den Boer and Renee X. De Menezes were responsible for designing the classifier.
- Brian V. Balgobind, Iris H.I.M. Hollink, Susan T.J.C.M. Arentsen-Peters, Jacqueline Cloos, were responsible for mutation analysis
- Susan T.J.C.M. Arentsen-Peters was responsible for microarray hybridization and data extraction.
- Elisabeth R. van Wering, Dirk Reinhardt, Jean-Michel Cayuela, Andre Baruchel, Jan Trka, Jan Stary were responsible for providing patient samples and patients' characteristics of study group patients.
- Claus Meyer, Rolf Marschalek were responsible for LDI-PCR
- H. Berna Beverloo was responsible for cytogenetic analysis of the samples.

4) **Results.** The following authors were responsible for specific portions of the results, including figures and tables (please indicate the person responsible for each figure and each table):

- Brian V. Balgobind and Monique L. den Boer were responsible for all results, figures and tables.

5) **Writing the manuscript.** The following authors were responsible for writing the manuscript:

- Brian V. Balgobind, Monique L. den Boer, Marry M. Van den Heuvel-Eibrink, C. Michel Zwaan, Rob Pieters were responsible for writing the manuscript

6) **Contributors Listed in Acknowledgments:** B.V.B was funded by the 'Netherlands Organisation for Scientific Research' (NWO). R.X.M. has been partially funded by the Dutch Cancer Society (grant EMCR 2005-3662) and the Center of Medical Systems Biology (CMSB) established by the Netherlands Genomics Initiative/Netherlands Organisation for Scientific Research (NGI/NWO). H.B.B. was partly funded by the Dutch Cancer Society (grant EMCR 2003-2871). This research was sponsored by a grant from the Quality of Life Foundation, the Netherlands (R.P, M.L.D.B.).